방사선종양학

본문글자크기
  • 2024년 09월호
    [Int J Radiat Oncol Biol Phys .] Liver-Directed Combined Radiation Therapy for Downstaging Beyond-Milan Hepatocellular Carcinoma to Liver Transplantation

    연세의대 / 김진아, 김용태, 성진실*

  • 출처
    Int J Radiat Oncol Biol Phys .
  • 등재일
    2024 Jul 15
  • 저널이슈번호
    119(4):1171-1178. doi: 10.1016/j.ijrobp.2024.01.221.
  • 내용

    바로가기  >

    Abstract
    Purpose: Curative surgery involving either resection or liver transplantation (LT) is indicated only for early-stage hepatocellular carcinoma (HCC). Over the years, numerous efforts have been made to downstage advanced HCC to curative surgery using various locoregional therapies. In this study, we investigated the role of liver-directed combined radiation therapy (LD-CRT) as a downstaging strategy for converting beyond-Milan advanced HCC to LT.

    Methods and materials: From January 2009 to February 2022, 53 patients with HCC who were initially beyond-Milan criteria were treated with LD-CRT and subsequent LT. These patients were compared with those who underwent upfront LT for within-Milan HCCs. The primary endpoint was overall survival (OS) and the secondary endpoint recurrence-free survival (RFS).

    Results: After LD-CRT, substantial downstaging was achieved in 35 patients (66%) who were initially beyond-Milan to within-Milan. At a median follow-up period of 47.6 months (range, 6.9-151.7 months), 5-year OS and 2-year RFS of the patients who received downstaging LD-CRT followed by LT were 66.9% and 63.2%, respectively. Patients who were successfully downstaged to within-Milan after LD-CRT had improved 5-year OS compared with their counterparts (81.9% vs 74.3%, P = .219). Recurrence after transplantation was observed in 18 patients (4 intrahepatic recurrences and 14 extrahepatic metastases).

    Conclusions: LD-CRT achieved favorable oncological outcomes as a downstaging strategy for LT in patients with beyond-Milan HCC. The findings of this study suggest that the active adoption of LD-CRT needs full consideration for patients with beyond-Milan HCC, presenting the possibility of curing patients with advanced HCC.

     

     

     

    Affiliations

    Jina Kim 1, Yong Tae Kim 1, Jae Geun Lee 2, Dai Hoon Han 2, Dong Jin Joo 2, Do Young Kim 3, Jinsil Seong 4
    1Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
    2Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
    3Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
    4Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. Electronic address: jsseong@yuhs.ac.

  • 덧글달기
    덧글달기
       IP : 18.97.14.85

    등록